Alternatively, a VHH that specifically targets the human FcγR III (CD16) fused to a tumor antigen-specific VHH could kill tumor cells by inducing ADCC and reduce tumor growth in mice that were xenografted with tumor cells and human PBMCs [89]. Here, FCGR3A is linked to neoplasm.